This trial is evaluating whether Lomustine will improve 1 primary outcome and 3 secondary outcomes in patients with Gliosarcoma. Measurement will happen over the course of Up to study completion, an average of 2 years.
This trial requires 10 total participants across 1 different treatment group
This trial involves a single treatment. Lomustine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"Lomustine, a bifunctional alkylating agent and antitumor antibiotic, has been used clinically for over 30 years and is currently no longer marketed because of severe side effects. A few case reports concerning an improvement of OS and PFS have been reported from the absence of chemotherapy and radiation therapy. However, the role of these agents as therapeutic agents remains undefined." - Anonymous Online Contributor
"The majority of patients were treated with lomustine plus radiotherapy or radiation alone. Patients who responded well to lomustine had better survival rates than those who did not respond to it at all. There was no significant difference between lomustine and lomustine + radiotherapy groups in terms of response rate or OS. Findings from a recent study suggest that lomustine can be administered as monotherapy in selected cases. However, patients should be carefully monitored during the administration of lomustine for side effects." - Anonymous Online Contributor
"The main risk factors for glioblastoma include age under 40 years (relative risk 1.2), male sex (relative risk 1.3) and low socioeconomic status (relative risk 1.2); race does not appear to be associated with glioblastoma." - Anonymous Online Contributor
"The clinical presentation of glioblastoma is variable, and the biologic heterogeneity is also large. Therefore, each patient should be treated individually based on his or her individual characteristics." - Anonymous Online Contributor
"Lomustine is an alkylating antineoplastic agent used as second line therapy after radiotherapy for recurrent neuroblastoma and in some cases Hodgkin disease. It is approved by the FDA for use in children < 18 years old in combination with chemotherapy for metastatic neuroblastoma. I have been prescribed this drug by my oncologist for over 5 years. A few years ago I was given a handful of pills each day for 7 days. In one month I restarted the use of the same amount of pills 3 times a day, over the course of 3 weeks, until the end of June when I decided to start taking just 1 pill each day. After 6 months I started taking 2 tablets every day." - Anonymous Online Contributor
"A pooled analysis suggests that the average age of patients diagnosed with glioblastoma is 63.6 years old; however, this might represent an age distribution skewed towards older patients. To improve outcomes, the average age at diagnosis should be used as a stratification factor in clinical trials evaluating immunotherapeutic agents targeting PDX1/EGFR." - Anonymous Online Contributor
"These data suggest that glioblastoma incidence rates have increased substantially during this period. Although these increases may be due to better detection, they also may be related to changes in socioeconomic and lifestyle factors. Further studies are needed to determine whether the increase in glioblastoma incidence in the United States reflects a true increase in incidence or merely improved detection." - Anonymous Online Contributor
"Besides the symptoms mentioned above that are common to all brain tumor patients, these multi-symptom cancers also have their own set of specific tasks that need to be performed before diagnosis can be made. The manifestations of GBM vary greatly among individuals; hence, clinicians must be aware of the unique pathologies that are associated with this disease so as to make the best decision concerning treatment options or potential cures." - Anonymous Online Contributor
"There are tremendous differences in the treatment regimens used in different countries, regions, and hospitals. A systematic review of the current practices can provide evidence-based recommendations for the treatment of GBM. Many of the treatments used have been shown to improve survival rates. However, there is no high-quality evidence that one regimen is better than another for the patient." - Anonymous Online Contributor
"Lomustine seems to have an acceptable toxicity profile for adult patients with recurrent GBM who require prolonged chemotherapy. However, further studies are needed to better define its role and safety profile." - Anonymous Online Contributor
"Results from a recent clinical trial of this study indicate that lomustine may be more effective than a placebo in treating patients with recurrent glioblastoma." - Anonymous Online Contributor